Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor.

  title={Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor.},
  author={Leslie J Lipka},
  journal={Cardiovascular drug reviews},
  volume={21 4},
Significant numbers of patients at risk for coronary heart disease (CHD) fail to reach National Cholesterol Education Program (NCEP)-designated low density lipoprotein cholesterol (LDL-C) goals in spite of the wide range of currently available treatments, including combination therapies. Ezetimibe, the first in a class of novel cholesterol absorption inhibitors, demonstrated lipid-lowering and antiatherosclerotic activity in experimental and clinical hypercholesterolemia. Studies in… CONTINUE READING